Based on some retrospective study data, the effectiveness of ICIs combined with chemotherapy in the first‐line treatment of advanced NSCLC patients with HER2 mutations remains controversial.16, 21. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.